Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26015662 | 0.88 | KDM4E (0.47) | KDM4EKMT2AMAPK14HPGDSMEN1 | |
| SCHEMBL15748102 | 0.86 | HPGDS (0.48) | KDM4EALDH1A1KMT2AMAPK14HPGDS | |
| SCHEMBL15748014 | 0.85 | HPGDS (0.60) | KMT2AHPGDSRIPK1L3MBTL1CYP4F2 | |
| SCHEMBL15133167 | 0.81 | GABRA5 (0.49) | KDM4EKMT2AMAPK14MEN1CYP2C9 | |
| SCHEMBL5423478 | 0.79 | KDM4E (0.72) | KDM4EALDH1A1KMT2ARIPK1L3MBTL1 | |
| SCHEMBL21553939 | 0.79 | SMN1; SMN2 (0.49) | KDM4EKMT2AMAPK14HPGDSL3MBTL1 | |
| SCHEMBL8872720 | 0.78 | KDM4E (0.57) | KDM4EALDH1A1MAPK14HPGDSL3MBTL1 | |
| SCHEMBL27117782 | 0.76 | KDM4E (0.51) | KDM4EALDH1A1KMT2ARIPK1L3MBTL1 | |
| SCHEMBL17059100 | 0.76 | P4HA1 (0.46) | ALDH1A1KMT2AL3MBTL1BAZ2B | |
| SCHEMBL17059686 | 0.76 | P4HA1 (0.66) | KDM4EALDH1A1CYP2C9BAZ2BHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732001-B2 | Methods of incorporating an amino acid comprising a BCN group into a polypeptide using an orthogonal codon encoding it and an orthogonal pylrs synthase | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732001-B2 | Methods of incorporating an amino acid comprising a BCN group into a polypeptide using an orthogonal codon encoding it and an orthogonal pylrs synthase | COASY, BCAT1, FARSA | KDM4E 703/4885ALDH1A1 4357/4885KMT2A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.